type 2 diabetes mellitus
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) age 20 to less than 80; 2) no change in oral antihyperglycemic drug therapy, lipid metabolism-improving drug therapy, or antihypertensive drug therapy during the 12 weeks preceding enrollment; and 3) ongoing treatment by diet regimen alone or by therapy with sulfonylurea, sulfonylurea plus biguanide, or sulfonylurea plus thiazolidine derivatives.
Exclusion criteria
Exclusion criteria: 1) receiving insulin therapy; 2) having diabetic ketoacidosis, nonketotic hyperosmolar coma, infection, or acute coronary syndrome; 3) being pregnant or possibly pregnant; 4) having a history of stroke or ischemic heart disease occurring within the preceding 6 months; 5) having a history of pancreatitis; and 6) having arrhythmia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the difference between changes in postprandial vascular endothelial function without eventide administration compared with single-dose exenatide administration. | — |
Countries
Japan
Contacts
School of Medicine, University of Occupational and Environmental Health First Department of Internal Medicine